T Cell Engagement and Activation: New Developments

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>T Cell Engagement and Activation: New Developments</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape."> <meta property="og:title" content="T Cell Engagement and Activation: New Developments"> <meta name="twitter:description" content="As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape."> <meta name="twitter:title" content="T Cell Engagement and Activation: New Developments"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/T-Cell-Engagement-and-Activation-New-Developments.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/T-Cell-Engagement-and-Activation-New-Developments.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> NextGen Therapeutics | Industry Spotlights & Insight Articles </div> <h1 class="heading"> T Cell Engagement and Activation: New Developments </h1> <div class="byline"> Edited by Cara Digby-Patel | 10 July 2023 </div> <div class="abstract"> As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/T-Cell-Engagement-and-Activation-New-Developments.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <p>In the ever-evolving landscape of cancer therapeutics, innovative approaches that harness the body's immune system to target tumours have gained significant attention. Among these groundbreaking strategies, cell engagers have emerged as a promising frontier, offering new hope in the fight against cancer. These agents leverage the natural cytotoxic abilities of immune cells to selectively eliminate malignant cells, regardless of the tumour type or its inherent immune evasion mechanisms.</p>   <p>This article delves into the transformative potential of cell engagers, specifically focusing on the extraordinary capabilities of bispecific antibodies. By bridging immune cells and cancer cells, bispecific cell engagers facilitate a direct connection, enabling the immune system to mount a potent attack against tumours. This dual-targeting approach enhances the specificity and efficacy of immune cell activation and opens new avenues for therapeutic interventions in various cancers, including hematologic malignancies and solid tumours.</p>   <p>In presentations at Oxford Global’s <strong>Biologics 2023</strong> and <strong>Immuno 2023</strong> events, we saw cutting-edge research on new T cell engager technologies presented by industry experts. In this Insight Article, we look at two of these presentations, delivered by Dan Snell, Vice President of Translational Sciences at Numab Therapeutics, and Rob Roovers, Senior Director of Preclinical Development at LAVA Therapeutics. </p>   <h2 id="h-presentation-1-t-cell-engager-design-and-combinations"><strong>Presentation 1: T Cell Engager Design and Combinations</strong></h2>   <p><em>Presented by: Dan Snell, Vice President of Translational Sciences at Numab Therapeutics at Biologics 2023</em></p>   <p>Numab Therapeutics, a clinical-stage multispecific antibody development company, is revolutionising cancer therapeutics through its proprietary pipeline of next-generation antibody-based therapeutics. The molecules designed by Numab have improved stability thanks to an engineering technique they have developed, whereby they alter the  sequence of the light chain of their single chain variable fragments. This step occurs alongside the humanisation process and allows the molecules to be reliably used as the basis for multispecifics therapeutics. </p>   <p>Snell discussed two of Numab’s lead molecules which demonstrate this improved stability and safety profile. He began by presenting on NM28, a mesothelin-targeting T cell engager. Mesothelin expression is associated with various difficult-to-treat cancers, including mesothelioma and pancreatic cancer. </p>   <p>NM28-2746 is a bivalent molecule that can discriminate between tumour cells expressing high levels of mesothelin and normal cells, which typically express low levels of the protein. As Snell put it, Numab has been working to “create a window of opportunity for the treatment, to be able to target cells with high densities of mesothelin.” Cell viability assays and T cell activation assays demonstrated that NM28 exhibited increased potency on tumour cells whilst sparing normal cells, thanks to its bivalent binding and higher complex stability. </p>   <p>Numab Therapeutics has also developed NM32, a TCE targeting ROR1, a protein associated with solid tumours and hematologic malignancies. NM32-2668, a monovalent ROR1 molecule, ensures constant efficacy irrespective of target expression levels. It induces specific killing of non-proliferating chronic lymphocytic leukaemia (CLL) patient samples and demonstrates tumour regression in a mantle cell lymphoma model.</p>   <ul> <li><a href="https://oxfordglobal.com/biologics/resources/the-bispecific-antibody-landscape/" target="_blank" rel="noreferrer noopener">The Bispecific Antibody Landscape</a></li>   <li><a href="https://oxfordglobal.com/biologics/resources/computational-tools-and-ai-ml-for-antibody-engineering/" target="_blank" rel="noreferrer noopener">Computational Tools and AI/ML for Antibody Engineering</a></li>   <li><a href="https://oxfordglobal.com/biologics/resources/bispecific-car-t-cell-therapies-successful-applications-in-mouse-tumour-models/" target="_blank" rel="noreferrer noopener">Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models</a></li> </ul>   <p></p>   <p>For both molecules, researchers at Numab explored their potential as combination immunotherapies. Strong anti-tumour activity was observed by combining NM28-2746 with a PD-L1/4-1BB bispecific antibody. This combination ultimately resulted in the remodelling of the tumour microenvironment, as it led to an increase in the number of CD3+ T cells and a decrease in CD4+ T cell counts within the tumour, thereby creating a hostile tumour microenvironment. </p>   <p>Similarly, when NM32 was combined with the same bispecific, researchers again observed strong anti-tumour inhibition, reflecting a high efficacy of engaging ROR1 at low dosing when in combination with PD-L1/4-1BB. </p>   <p>This research shows the potential of combination therapies using T cell engagers. Numab’s groundbreaking approaches hold great promise in addressing the challenges posed by diverse tumour types and advancing towards more effective and personalised cancer therapies. </p>   <h2><strong>Presentation 2: Development of V?9V?2 T Cell-Engaging Bispecific Antibodies for Efficacious Cancer Treatment</strong></h2>   <p><em>Presented by: Rob Roovers, Senior Director Preclinical Development at LAVA Therapeutics at Immuno 2023</em></p>   <p>V?9V?2-T cells, a subset of ??-T cells, have emerged as critical players in antitumor immunity. These cells exhibit consistent pro-inflammatory cytotoxic effector functions and unique antigen-presenting abilities. Studies have shown that the presence of V?9V?2-T cells in tumour tissue is associated with a favourable prognosis for cancer patients.</p>   <p>LAVA Therapeutics is a biopharmaceutical company that has leveraged the potent antitumor capabilities of V?9V?2-T cells to develop a bispecific CD123 targeting V?9V?2 T cell engager. CD123, also known as interleukin-3 receptor-alpha, is expressed in many haematological malignancies, including acute myeloid leukaemia and Hodgkin's lymphoma.</p>   <p>Roovers explained how the bispecific V?9V?2 T cell engager aims to enhance T cell engagers' specificity and therapeutic window. Unlike traditional approaches, this novel engager aims to retain potency while increasing tumour specificity and avoids the activation of regulatory T cells. Additionally, it can potentially stimulate downstream immune activation such as antigen presentation.</p>   <p>LAVA has employed two formats for their bispecific V?9V?2 T cell engagers. The first format utilises a bispecific single-domain antibody, which exhibits high affinity binding and potency. This molecule, smaller than regular IgG1 and BiTE formats, is being used in their haematological program. The second format combines a bispecific single-domain antibody with an Fc domain. This format also demonstrates high affinity binding and potency, with an <em>in vivo</em> half-life similar to canonical IgG1. It is being employed in their lead solid tumour program.</p>   <p>In preclinical studies, the V?9V?2 T cell engager has shown promising results. The engager binds to CD123 and exhibits high potency in killing CD123+ tumour cells. Importantly, it demonstrates tumour cell selectivity, relatively sparing CD123+ healthy cells from lysis. This selective targeting indicates that the therapy has the potential to be studied clinically.</p>   <p>Furthermore, the CD123 targeting V?9V?2 T cell engager developed by LAVA does not block IL-3-induced proliferation, indicating that it may not interfere with the normal function of IL-3, which is a crucial driver of haematopoiesis.</p>   <p>Overall, LAVA's bispecific CD123 targeting V?9V?2 T cell engager reflects a “strong scientific and clinical rationale for tumour targeted engagement of V?9V?2 T cells,” thanks to the potential for an improved safety profile of such therapies. LAVA has already finished its cell line development and begun preclinical development. They expect to be ready to file a clinical trial application for the molecule in 2024. </p>   <p><em>Want to know more about Oxford Global’s upcoming <a href="https://oxfordglobal.com/vaccines/" target="_blank" rel="noreferrer noopener">Vaccines Europe</a> event? Download the <a href="https://oxfordglobal.com/vaccines/agenda/download-agenda/" target="_blank" rel="noreferrer noopener">agenda</a> or <a href="https://oxfordglobal.com/vaccines/book-now/" target="_blank" rel="noreferrer noopener">register today</a> to join prominent leaders and scientists as they share new case studies, innovative data, and exciting industry outlooks.</em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-event"> <h3 class="center">Related Events</h3> For more on this topic, you may be interested in our upcoming <a href="/nextgen-biomed/events/nextgen-biomed-2025">Proteins & Antibodies</a> </div> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Bispecific-T-Cell-Engagers-Synthetic-Immunity-Halting-Immune-Escape-rotated.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <h4> Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape </h4> <div class="abstract"> Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-T-Cell-Engagers-and-Primers-scaled.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <h4> Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment </h4> <div class="abstract"> Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies? </div> <div class="read-more"> <a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/t-cell-engagement-and-activation-new-developments"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999708"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999708", "legacyPageId": "hubdb-177607186815-30817717-181072999708", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "6e4fe2eb-3f3a-4b19-b291-06031ab306ea", ticks: 1732703953045, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999708", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999708", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

T Cell Engagement and Activation: New Developments